Abstract

The outbreak of COVID-19, caused by a novel virus, has led to a global pandemic with significant implications for public health. COVID-19 exhibits a wide range of manifestations, affecting multiple organs in addition to the respiratory system. Cardiovascular complications, including myocarditis, have been observed in a substantial proportion of hospitalized COVID-19 patients and are associated with adverse outcomes. Studies have reported varying rates of myocarditis incidence among COVID-19 patients, with seasonal variations and higher numbers observed in the summer. The relative numbers of myocarditis cases are highest in younger individuals, but the in-hospital case-fatality rate increases with age. COVID-19 patients with myocarditis are more likely to require intensive care and ventilation support. Myocarditis is independently associated with increased case-fatality and the occurrence of venous thromboembolism in COVID-19 patients. Understanding the incidence and prevalence of myocarditis in COVID-19 is essential for patient management and prognosis.

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call